Early trial tests cancer drug safety for patients with liver issues
NCT ID NCT07036133
Summary
This early-stage study aims to understand how the cancer drug pralatrexate is processed by the body in people with varying degrees of liver impairment. It will involve about 24 adults with advanced solid tumors or blood cancers. The main goal is to measure drug levels in the blood and check for safety to help determine appropriate future doses for patients with liver problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gabrail Cancer Center
RECRUITINGCanton, Ohio, 44718, United States
Contact
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Northwestern University - Feinberg School of Medicine
RECRUITINGChicago, Illinois, 60611, United States
Contact
-
TOI Clinical Research
WITHDRAWNCerritos, California, 90703, United States
Conditions
Explore the condition pages connected to this study.